Hypothesis

Lactate‑producing Lactobacillus strains engineered to overexpress lactate dehydrogenase (LDH) increase circulating lactate, which crosses the blood‑brain barrier via MCT1 transporters and activates neuronal mTORC1 signaling, leading to improved spatial memory in individuals whose baseline microbiome lacks high lactate‑producing taxa.

Rationale

• Strain‑specific psychobiotics such as L. rhamnosus GG reduce MCI‑associated Prevotella ruminicola and improve cognition Lactobacillus rhamnosus GG improves cognition.
• Lactate functions as a signaling molecule that can stabilize HIF‑1α and activate mTOR pathways in neurons Lactate signaling and mTOR.
• Precision microbiome approaches now target functional genes rather than taxa Precision microbiome targeting. LDH is a measurable functional marker.
• Individuals with low endogenous lactate producers exhibit blunted BDNF responses to generic probiotics Low lactate producers and BDNF.
• Animal models demonstrate that enhancing gut‑brain lactate flux reverses age‑related cognitive decline Gut‑brain lactate flux reverses decline.

Mechanistic Insight

Engineered LDH‑high lactobacilli raise luminal lactate → absorption via monocarboxylate transporter 1 (MCT1) in enterocytes → portal lactate elevation → hepatic release into systemic circulation → BBB crossing via endothelial MCT1 → neuronal uptake → lactate‑driven HIF‑1α stabilization → mTORC1 activation → synaptic protein synthesis and dendritic spine remodeling → enhanced spatial memory.

Testable Predictions

1. Participants receiving the LDH‑high strain will show a ≥20 % increase in fecal lactate and plasma lactate versus placebo after 4 weeks.
2. Elevated plasma lactate will correlate with increased phospho‑S6K (a downstream mTOR readout) in peripheral blood mononuclear cells.
3. Cognitive testing (virtual navigation task) will reveal significantly better spatial memory scores in the treatment group, mediated by lactate change.
4. Individuals whose baseline metagenome shows low abundance of LDH‑encoding genes will derive the greatest benefit, establishing a genotype‑by‑treatment interaction.

Experimental Design

• Double‑blind, placebo‑controlled crossover trial (n = 120) aged 60‑80 with mild cognitive impairment.
• Stratify by baseline metagenomic LDH gene abundance (high vs low).
• Intervention: daily sachet containing 10⁹ CFU of LDH‑overexpressing L. plantarum; placebo: identical sachet without live bacteria.
• Duration: 8 weeks per arm, 4‑week washout.
• Outcomes: fecal lactate (GC‑MS), plasma lactate (enzymatic assay), phospho‑S6K flow cytometry, BDNF serum ELISA, virtual navigation performance, fMRI hippocampal activation.
• Statistical plan: mixed‑effects model testing treatment, lactate change, and their interaction on cognition; mediation analysis to assess lactate as mediator.

Potential Confounders and Controls

• Dietary lactate sources standardized via low‑lactate meal plan.
• Antibiotics or probiotics use prohibited 4 weeks prior.
• Host genetics (MCT1 polymorphisms) genotyped and included as covariate.
• Safety monitored via adverse event logs and routine labs.

Falsifiability

If the LDH‑high strain fails to raise lactate levels, or lactate elevation does not predict mTOR activation or cognitive improvement, the hypothesis is refuted. Likewise, a lack of interaction between baseline LDH gene abundance and treatment effect would undermine the precision‑targeting premise.